MGFR1877S is an mAb targeting FGFR3 by hampering its dimerization, which is well tolerated with low toxicities in patients with multiple myeloma and solid tumors in phase I clinical trials.708. The gene discussed is FGFR3; the disease is AL amyloidosis.